RecruitingNCT07508319
Role of the Immune System in Preventing Laryngeal Cancer
Laryngeal Dysplasia and Progression to Carcinoma: Investigating Genetic and Immune Alterations Predictive of Malignant Transformation
Sponsor
European Institute of Oncology
Enrollment
3 participants
Start Date
Nov 19, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Laryngeal dysplasia and progression to carcinoma: investigating genetic and immune alterations predictive of malignant transformation
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria2
- Histopathological diagnosis of laryngeal dysplasia.
- Age >18 years and informed consent.
Exclusion Criteria5
- Prior surgical, radiotherapeutic, or oncologic treatments for head and neck regions.
- Congenital or acquired immunodeficiency disorders.
- Synchronous malignancies.
- Immunosuppressive therapy.
- Age <18 years or absence of research consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07508319
Related Trials
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
NCT074450481 location
Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT
NCT074487271 location
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
NCT072921685 locations
Improving Dental Care for Patients With Head and Neck Tumors
NCT073283471 location
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
NCT073537231 location